|Awaiting HTA submission from Applicant
|For the treatment of adult patients with advanced RET fusion-positive thyroid cancer who require systemic therapy following prior treatment with lenvatinib and/or sorafenib.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of selpercatinib compared with the current standard of care.
|Full pharmacoeconomic assessment commissioned by HSE
|Pre-submission consultation with Applicant
The company has not submitted a HTA dossier to the NCPE, therefore the cost effectiveness of the technology could not be proven.